TF and Alzheimer disease: modified Tf on nanostructured lipid carriers (Tf‐NLCs) encapsulating two drugs, rivastigmine hydrogen tartrate and resveratrol, for AD treatment.[89] Their study found that TF‐NLCs demonstrated a significantly slow release compared to NLCs and revealed significantly higher (≈1.7‐fold) brain uptake of Tf‐NLCs compared to NLCs in vivo after intraperitoneal administration.